Palbociclib combined with fulvestrant and goserelin was an effective and well-tolerated treatment for premenopausal women with prior endocrine-resistant HR+/HER2 ABC. Inclusion of both premenopausal and postmenopausal women in pivotal combination ET trials facilitates access to novel drugs for young women and should be considered as a new standard for clinical trial design.
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Implications for Practice
PALOMA-3, the first registrational study to include premenopausal women in a trial investigating a CDK4/6 inhibitor combined with endocrine therapy, has the largest premenopausal cohort reported in an endocrine-resistant setting. In pretreated premenopausal women with HR+ ABC, palbociclib plus fulvestrant and goserelin (LHRH agonist) treatment almost doubled median PFS and significantly increased the objective response rate vs endocrine monotherapy, achieving results comparable to those reported for chemotherapy without apparently interfering with LHRH agonist-induced ovarian suppression. The significant PFS gain and tolerable safety profile, strongly supports use of this regimen in premenopausal women with endocrine-resistant disease who could possibly delay chemotherapy.
Learning Objectives
BEST PRACTICE CURRENT PRACTICE RESULTING GAPS LEARNING OBJECTIVES
Premenopausal women with HR+ MBC should be offered ovarian suppression or ablation in combination with hormone therapy.
For premenopausal patients whose disease progresses on prior endocrine therapy, and for whom subsequent hormone therapies are indicated for their MBC, ovarian suppression should be maintained during treatment.
Measurements of estradiol and FSH at baseline, before a premenopausal patient initiates treatment with a LHRHa and aromatase inhibitor, has been recommended.
Sources:
Rugo HS, Rumble RB, Macrae E, et al. Before the PALOMA-3 study, trials of clinical importance to investigate the effects of endocrine-based therapies on advanced breast cancer have been designed to only permit the participation of postmenopausal women, or less commonly, women who reach menopause prematurely owing to treatment-related ovarian failure.
Source:
Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormonereceptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-439.
Questions persist because clinically important data are lacking in the current era to demonstrate the effects of endocrine therapy on premenopausal women with ABC.
Premenopausal women with heavilypretreated HR+ ABC and prior disease progression because of endocrine resistance require additional targeted treatment options that can extend the duration of an effective endocrine-based therapy with a tolerable safety profile and delay the need for chemotherapy if a rapid response is not required.
Rugo for HR+/HER2-ABC (PALOMA-3 trial: fulvestrant vs fulvestrant + palbociclib [6, 23] ).
In the randomized, phase 3 PALOMA-3 trial, palbociclib plus fulvestrant (± goserelin) prolonged investigator-assessed PFS compared with placebo plus fulvestrant (± goserelin) in women with HR+/HER2-ABC after prior progression on ET (median PFS 9.5 vs 4.6 months, respectively, hazard ratio, [HR] 0.46 [95% CI: 0.36-0.59], 2-sided log-rank P<.0001). [6] PALOMA-3 was the first registrational study to include premenopausal women in this setting;
herein we describe the results by menopausal status, with a focus on premenopausal women with prior endocrine-resistant HR+/HER2 ABC.
PATIENTS AND METHODS
PALOMA-3 Study Design and Patients
The design of the PALOMA-3 phase 3, randomized, double-blind, placebo-controlled trial and definitions of the efficacy and safety parameters assessed have been described in detail elsewhere. [6, 23] and on day 1 of cycle 3 for the assessment of trough concentrations (C trough ) of palbociclib, fulvestrant, and goserelin (when applicable) in a subgroup of ~40 patients included in an initial interim safety assessment. Additional PK samples for plasma C trough of palbociclib were drawn on day 15 of cycles 1 and 2 from all remaining patients.
Statistical Analysis
The Kaplan-Meier method[24] was applied to estimate median PFS (mPFS) and generate survival curves. A 2-sided unstratified log-rank test was used to compare treatment arms by menopausal status and a 1-sided unstratified log-rank test was used to compare treatment arms in subsets of premenopausal and postmenopausal patients ≤50 years as part of an exploratory analysis. The hazard ratio was estimated from the Cox proportional hazards regression model.
Clinical benefit response (CBR) and objective response rate were evaluated and compared between treatment arms using a 1-sided exact test stratified by the presence of visceral metastases and sensitivity to prior hormonal therapy per randomization. A multivariate analysis was run to evaluate the relationship between baseline prognostic factors with PFS. The final explanatory variables for the model were acquired using a backward selection process with a 0.1 significance level required for retaining the effects in the model. Descriptive analysis was used to summarize maximum-grade treatment-emergent adverse events (AEs). Biochemistry data were summarized and t tests (one for each hormone) were used to compare data between treatment arms without a multiplicity adjustment for these or other exploratory analyses. The analyses for the potential for drug-drug interactions (DDIs) are described in detail in the appendix (supplementary text, online only). Statistical analyses were performed using SAS ® Version 9.2 (SAS Institute, Cary, NC).
Before any study procedures were initiated, all patients provided written informed consent.
Institutional review boards at participating centers approved all study-related procedures, which were conducted in accordance with the International Conference on Harmonisation, the guidelines for Good Clinical Practice, and the Declaration of Helsinki. Study enrollment is closed and the trial met its primary endpoint at interim analysis. The overall survival follow-up is in progress.
RESULTS
Between October 7, 2013, and August 26, 2014, 521 patients were randomly assigned to receive palbociclib plus fulvestrant (347 patients) or placebo plus fulvestrant (174 patients) with or without goserelin [6] (Appendix Fig. A1 , online only).
Patient Demographics
A total of 108 (21%) women were premenopausal and 413 (79%) were postmenopausal. Overall, 42 (8%) women were ≤40 years, and 163 (31%) women were ≤50 years. Among premenopausal women, the mean age was 45 years; 83 (80%) of these patients were ≤50 years. Among postmenopausal women, 80 (19%) patients were aged ≤50 years. Demographic and baseline characteristics are shown by menopausal status in Table 1 . Half of the premenopausal women had received both tamoxifen and AI before enrollment. Baseline characteristics between treatment arms within menopausal subgroups were well balanced, except more premenopausal women had 2 prior lines of therapy in the ABC setting in the palbociclib than in the placebo arm (31.9% and 19.4%, respectively). Baseline characteristics between premenopausal and postmenopausal women were also well balanced, although the ESR1 mutation rate by cfDNA was slightly lower in premenopausal women.
Efficacy
The data cutoff for this analysis was 
1.[25]
In the palbociclib arm vs the placebo arm, investigator-assessed objective responses were observed in 25.0% (18/72) vs 11.1% (4/36) of premenopausal patients, respectively (odds ratio, Fig 1C) .
Prognostic Factors
Important and favorable prognostic factors in the final Cox proportional hazards multivariate model included absence of visceral disease for both premenopausal and postmenopausal patient subpopulations and Asian ethnicity for premenopausal patients. The treatment effect of palbociclib plus fulvestrant seen in the primary analysis of PFS held when the important prognostic factors were simultaneously adjusted in the multivariate analyses for both premenopausal and postmenopausal patients (Table 2) . When BMI was examined with the treatment arm in a separate multivariate model, lower values were more favorable for PFS.
Safety
Although all premenopausal women received goserelin concurrently with palbociclib plus fulvestrant, the safety profile was similar to that of postmenopausal women in terms of the type and frequency of AEs (all grades and grade 34), serious AEs (SAEs), the rate of dose reductions, cycle delays. Dose interruptions and discontinuation rate due to AEs were also similar for the palbociclib arm between menopausal subgroups (premenopausal, 5.6% and postmenopausal, 4.7%) ( Table 3 ).
Biochemical Analysis
After 15 days of study treatment, there was no significant difference in the mean concentrations of LH, FSH, or plasma E2 between those premenopausal patients receiving palbociclib or not; all unadjusted P values from the t tests were >0.05 (Fig. 3) . Mean E2 concentrations were consistent with those expected in the postmenopausal range. One patient in the palbociclib arm had an E2 value of 93.5 pg/mL, more than 3 times the upper limit of that group and not consistent with ovarian suppression. There was a statistically significant correlation between plasma E2 levels and body mass index (BMI) in both treatment arms (Spearman's rho = .44, P=.002 and .49,
P=.02, respectively).
Drug-Drug Interaction Assessment
Results of the 1-way analysis of variance (ANOVA) and analysis of covariance (ANCOVA) analyses conducted to investigate the potential for DDIs among palbociclib, fulvestrant, and goserelin are shown in Appendix Table A1 (online only). The ratio of the adjusted geometric means (90% CI) for palbociclib from the final ANCOVA model and the within-patient mean steady-state concentration trough (C troughSS ) in the presence and absence of goserelin was 88.3%
(78.6%99.1%). The ratio of the adjusted geometric means (90% CI) for goserelin within-patient mean C troughSS in the presence and absence of palbociclib was 110% (54.2%-225%). For the ratio of the adjusted geometric means (90% CI) for palbociclib from the final ANCOVA model, the within-patient mean C troughSS in the presence and absence of fulvestrant was 128% (117%140%). The ratio of the adjusted geometric means (90% CI) for fulvestrant withinpatient mean C troughSS in the presence and absence of palbociclib was 122% (101%-147%).
DISCUSSION
We report the results of the largest cohort of premenopausal women with prior endocrineresistant HR+/HER2− ABC ever studied. The study found that premenopausal patients who to date to report outcomes data for fulvestrant 500 mg with ovarian suppression in premenopausal patients. [6] In premenopausal women in the control arm, mPFS with fulvestrant was 5.6 months. Accordingly, the fulvestrant label approved by the US Food and Drug Administration was recently expanded to include premenopausal women who receive concurrent ovarian suppression. [34] Because of the low potential for a DDI between the protocol-specified concomitant medications and palbociclib based on their metabolic pathways and ability to affect the activity of relevant metabolic enzymes, this study was designed with the intention of confirming the lack of clinically significant DDIs using a sparse PK sample collection (C troughSS only) for each analyte.
The magnitude of the ratios of the adjusted geometric means for the ANOVA and ANCOVA DDI analyses was not considered to represent a clinically meaningful difference.
The PK data confirms there were no clinically significant metabolic DDIs between palbociclib and goserelin or between palbociclib and fulvestrant when these 2 drugs were coadministered.
Furthermore, the coadministration of goserelin did not have a clinically significant impact on fulvestrant plasma PK.
The clinical effectiveness of luteinizing hormone-releasing hormone agonists depends on their suppression of ovarian steroidogenesis. There is evidence that although these agents achieve complete cessation of ovarian E2 synthesis by the end of the first month of treatment, partial recovery can occur in some patients, apparently driven by progressive recovery of FSH levels. [35] Combining a luteinizing hormone-releasing hormone agonist with fulvestrant could still potentially result in incomplete ovarian suppression if E2 and FSH levels increase in response to fulvestrant. [35] We report hormonal concentrations measured after 15 days of fulvestrant treatment but after ≥6 weeks on goserelin, given goserelin was started 4 weeks before the study commenced. It is also important to note that the levels of E2 were measured with a highly sensitive GC/MS-MS, which avoids cross reactions with fulvestrant or its metabolites that can lead to highly aberrant values that more commonly occur using immunoassays. [36, 37] Only one of 48 patients (2%) treated with palbociclib plus fulvestrant had an E2 value that was clearly premenopausal, but otherwise the values assessed for all patients were consistent with full ovarian function suppression, and there was no difference associated with the addition of palbociclib. This is supported by the significant relationship between plasma E2 levels and BMI; extragonadal estrogen production occurs mainly in subcutaneous fat [38] and resulting plasma concentrations are known to correlate with BMI. 
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The FSH, LH, and E2 data in the manuscript were generated by the Centre Royal Marsden Abbreviations: E2, estradiol; FSH, follicle-stimulating hormone; IQR, interquartile range; LH, luteinizing hormone; max, maximum; min, minimum.
a Six patients had E2 concentrations that were not considered valid (ie, below the quantification limit of 1.25 pg/mL or a volume too small for reanalysis). Tables   Table 1 h Not all patients had cfDNA samples; the data represent a subset of patients only. a Percentages are calculated in reference to n, and values include data up to 28 days after the last dose of study drug.
b Events coded using the Medical Dictionary for Regulatory Activities (version 18.0) PTs, including clusters of PTs, and by maximum Common
Terminology Criteria for Adverse Events grade.
c Average daily dose administered = (total dose administered)/(total days on drug). Days on drug is defined as the total number of days on which the drug was actually administered.
d Clustered PTs: Anemia refers to any event having a PT equivalent to anemia or hematocrit decreased or hemoglobin decreased; infections is any event having a PT part of the system organ class infections and infestations; leukopenia is any event having a PT equivalent to leukopenia or white blood cell count decreased; neutropenia is any event having a PT equivalent to neutropenia or neutrophil count decreased. Rash is any event having a PT equivalent to dermatitis or dermatitis acneiform or rash or rash erythematous or rash maculopapular or rash papular or rash pruritic; stomatitis is any event having a PT equivalent to aphthous stomatitis or cheilitis or glossitis or glossodynia or mouth ulceration or mucosal inflammation or oral pain or oropharyngeal discomfort or oropharyngeal pain or stomatitis; thrombocytopenia is any event having a PT equivalent to platelet count decreased or thrombocytopenia.
e Grade 5 events: in the palbociclib plus fulvestrant arm of the study, 2 (2.8%) premenopausal women had disease progression, and 1 (1.4%) premenopausal woman with disease progression also had hepatic failure; among postmenopausal women in the palbociclib plus fulvestrant arm, 1 (0.4%) had disseminated intravascular coagulation and 1 (0.4%) experienced general or physical health deterioration; among postmenopausal women in the placebo arm of the study, 1 (0.7%) had acute respiratory distress, 1 (0.7%) had breast cancer, and 1 (0.7%) had a cerebral hemorrhage. 
Supplementary Text
Drug-Drug Interactions
Potential for drug-drug interactions (DDIs) on the analytes palbociclib, fulvestrant, and goserelin was assessed using a 1-way analysis of variance (ANOVA) to analyze the natural log-transformed C trough with unique drug combination as a single factor. Additionally, the potential for DDIs to affect the PK of palbociclib was assessed using an analysis of covariance (ANCOVA) model to analyze the natural log-transformed C trough with unique drug combination as a main effect along with age and baseline body weight, the only covariates found to be statistically significant in a prior palbociclib population PK model, [42] were covariates in the full model.
Regression analyses were performed on the natural log-transformed C trough against unique drug combinations, and covariates identified using a backward selection process remained in the final ANCOVA model. The input for each statistical model was the within-patient mean of 2 steady-state (SS) C troughs for each analyte. For analyses using palbociclib PK, data from PALOMA-3 comprised the test group and historical data comprised the reference group. For analyses using fulvestrant and goserelin, PK comparisons were made across palbociclib and placebo treatment arms. A data cutoff of December 5, 2014 was used for the analyses of potential DDIs. 
